Results for tag: "Glucagon Receptor Antagonist"

The Glucagon Receptor Antagonist market is a subset of the Endocrine and Metabolic Disorders Drugs market. Glucagon Receptor Antagonists are drugs used to treat type 2 diabetes, a chronic metabolic disorder. These drugs work by blocking the action of glucagon, a hormone that increases blood sugar levels. By blocking the action of glucagon, these drugs can help to reduce blood sugar levels and improve glycemic control. Glucagon Receptor Antagonists are typically used in combination with other diabetes medications, such as insulin or metformin, to help control blood sugar levels. They are also used to reduce the risk of cardiovascular complications associated with diabetes. Some of the companies in the Glucagon Receptor Antagonist market include Novo Nordisk, Eli Lilly, Merck, Sanofi, and AstraZeneca. Show Less Read more